CCL5–CCR5 signaling facilitates the immunosuppressive polarization of monocytes and myeloid cells, contributing to an immunosuppressive TME in various cancers, including breast cancer, colorectal cancer, and Hodgkin lymphoma [42–44]. This evidence concerns the gene CCL5 and breast cancer.